Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia. Market research commissioned by Acasti* suggests there is an important market need for an effective, safe and well-absorbing omega-3 therapeutic with a positive impact on the major lipids associated with cardiovascular disease risk. Since August 2008, Acasti is focused on addressing this important unmet market need. Source
No articles found.
Tenax Therapeutics is focused on developing and commercializing pharmaceutical pro...
Tenax Therapeutics is focused on developing and...
Fibrocell is a cell and gene therapy company focused on improving the lives of peo...
Fibrocell is a cell and gene therapy company fo...
Galmed is a clinical-stage biopharmaceutical company focused on the development of...
Galmed is a clinical-stage biopharmaceutical co...
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Join the National Investor Network and get the latest information with your interests in mind.